The stock of Ignyta Inc (NASDAQ:RXDX) is a huge mover today! About 58,466 shares traded hands. Ignyta Inc (NASDAQ:RXDX) has declined 40.06% since April 5, 2016 and is downtrending. It has underperformed by 42.01% the S&P500.
The move comes after 5 months positive chart setup for the $194.70 million company. It was reported on Nov, 7 by Barchart.com. We have $9.37 PT which if reached, will make NASDAQ:RXDX worth $186.91 million more.
Analysts await Ignyta Inc (NASDAQ:RXDX) to report earnings on November, 14. They expect $-0.66 earnings per share, down 34.69% or $0.17 from last year’s $-0.49 per share. After $-0.68 actual earnings per share reported by Ignyta Inc for the previous quarter, Wall Street now forecasts -2.94% EPS growth.
Ignyta Inc (NASDAQ:RXDX) Ratings Coverage
Out of 6 analysts covering Ignyta (NASDAQ:RXDX), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Ignyta has been the topic of 10 analyst reports since August 12, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Jefferies given on Friday, October 23. The firm has “Buy” rating by Cantor Fitzgerald given on Tuesday, November 10. Credit Suisse maintained it with “Outperform” rating and $17 target price in Tuesday, March 15 report. The firm has “Buy” rating by Cantor Fitzgerald given on Monday, October 26. Piper Jaffray maintained the shares of RXDX in a report on Wednesday, August 12 with “Overweight” rating. The stock of Ignyta Inc (NASDAQ:RXDX) has “Overweight” rating given on Thursday, June 23 by JP Morgan. The firm earned “Buy” rating on Monday, October 26 by Canaccord Genuity. On Thursday, January 21 the stock rating was initiated by Credit Suisse with “Outperform”.
According to Zacks Investment Research, “Ignyta, Inc. is a biotechnology company. It develops precision medicine with integrated Rx/Dx solutions for cancer patients. The company focuses on the development of RXDX-101, its proprietary oral tyrosine kinase inhibitor that targets solid tumor indications, and advancing its novel Spark discovery programs that leverage its proprietary cancer genomic and epigenomic knowledge bases. Ignyta, Inc. is based in San Diego, California.”
Insitutional Activity: The institutional sentiment increased to 2.87 in 2016 Q2. Its up 1.47, from 1.4 in 2016Q1. The ratio is positive, as 6 funds sold all Ignyta Inc shares owned while 9 reduced positions. 11 funds bought stakes while 32 increased positions. They now own 24.37 million shares or 38.14% more from 17.64 million shares in 2016Q1.
Blackrock Institutional Co Na accumulated 521,104 shares or 0% of the stock. Ubs Oconnor Lc accumulated 34,056 shares or 0% of the stock. State Bank Of America Corporation De holds 3,306 shares or 0% of its portfolio. Tfs Cap Limited Liability Corp has 0.07% invested in the company for 65,576 shares. Ladenburg Thalmann Fincl Ser has invested 0% of its portfolio in Ignyta Inc (NASDAQ:RXDX). Baker Bros Limited Partnership, a New York-based fund reported 571,000 shares. Blackrock Japan reported 1,754 shares or 0% of all its holdings. Tang Management Lc holds 3.97M shares or 9.59% of its portfolio. State Street Corporation last reported 0% of its portfolio in the stock. Sabby Management Limited Liability Company owns 225,000 shares or 0.06% of their US portfolio. Tiaa Cref Invest Management Ltd Liability last reported 127,641 shares in the company. D E Shaw last reported 24,867 shares in the company. Art Advsr Limited Company accumulated 81,888 shares or 0.02% of the stock. Broadfin Cap Llc last reported 1.19% of its portfolio in the stock. Acuta Cap Partners Ltd Liability Corp holds 229,748 shares or 0.6% of its portfolio.
More important recent Ignyta Inc (NASDAQ:RXDX) news were published by: Marketwatch.com which released: “Virtual Stock Exchange” on December 06, 2013, also Fool.com published article titled: “Why Ignyta Inc. Shares Are Skyrocketing Higher”, Businesswire.com published: “Ignyta Announces Initiation of STARTRK â€œNext Generationâ€ Phase 1/1b Pediatric …” on December 09, 2015. More interesting news about Ignyta Inc (NASDAQ:RXDX) was released by: Seekingalpha.com and their article: “Ignyta Is Proof That Biotech Bargains Still Exist” with publication date: August 31, 2016.
RXDX Company Profile
Prometheus RxDx Corp., incorporated in June 2009, is a wholly owned subsidiary of Prometheus Laboratories Inc. The Firm is engaged in the development and commercialization of pharmaceutical and diagnostic products that enable physicians to provide individualized patient care. It focuses on the detection, diagnosis and treatment of disorders within the fields of gastroenterology and oncology. It operates in two divisions: the pharmaceutical products segment that markets and sells prescription drugs, and the diagnostic testing services segment, which includes specific immunoassays to detect and differentiate diseases, pharmacogenetic testing and drug metabolite monitoring. The pharmaceutical products for gastrointestinal diseases and disorders includes ENTOCORT EC (budesonide) Capsules, which is indicated for the treatment of mild to moderate active Crohnâ€™s disease involving the ileum and/or the ascending colon, and LOTRONEX (alosetron hydrochloride) Tablets, for use in female patients with severe diarrhea-predominant irritable bowel syndrome (IBS).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.